Armored immune cells take on liver cancer in early trial
NCT ID NCT05155189
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-phase study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to standard therapies. C-CAR031 uses a patient's own immune cells, modified to better target and attack cancer cells. The trial will enroll 72 participants to evaluate safety and whether the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of Zhengzhou University
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
C-CAR031 (armored CAR-T cells targeting GPC3)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 72 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.